Navigation Links
Onyx Pharmaceuticals Reports 2008 First Quarter Results
Date:5/6/2008

Nexavar Net Sales increase 149% over First Quarter 2007

EMERYVILLE, Calif., May 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today reported its financial results for the first quarter ended March 31, 2008. Onyx reported net income of $15.4 million, or $0.27 per diluted share, for the first quarter of 2008 compared to a net loss of $12.2 million, or $0.26 per diluted share, in the same period in 2007.

Nexavar net sales as reported by Bayer HealthCare Pharmaceuticals, Inc., or Bayer, were $151.9 million for the first quarter ended March 31, 2008, a 149% increase over the $60.9 million reported in the same period in 2007. Onyx with its collaborator, Bayer, is marketing and developing Nexavar(R) (sorafenib) tablets, an anticancer therapy currently approved for the treatment of liver cancer and advanced kidney cancer in the United States, European Union, and other territories internationally.

"We are pleased with Nexavar's strong performance in the first quarter of 2008, generating worldwide net sales of $151.9 million, which we attribute to the continued successful launch of Nexavar in liver cancer in both the United States and in the rest of the world," said Tony Coles, M.D., president and chief executive officer of Onyx. "While we continue the global launch of Nexavar in liver cancer, we are focusing commercial efforts on the further development of this new market to support the long-term growth of this important opportunity. At the same time, we are investing in a broad clinical program to realize the potential benefits of Nexavar in numerous other tumor types."

The net profit for the first quarter ended March 31, 2008, included employee stock-based compensation expense of $5.2 mil
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... NEW YORK , March 31, 2015 /PRNewswire/ ... biopharmaceutical company advancing protein biologic therapies and oncology ... marketing partner, Hanmi Pharmaceutical Co., Ltd ("Hanmi") (KSE: ... the country,s Ministry of Food and Drug Safety ... (KTR) for MuGard, its oncology supportive-care treatment for ...
(Date:3/31/2015)... This June 13th, a distinguished group of ... International Medical Schools will come together in Santa Monica, ... of stem cell therapy in treatments and cures for ... by the Ocular Research Symposia Foundation, Inc. ... meetings of top experts in the field of eye ...
(Date:3/31/2015)... 2015 Diasome Pharmaceuticals, Inc. ( http://www.diasome.com ... that a United States patent has recently been allowed ... , Entitled “Lipid Construct for Delivery of Insulin ... claims related to the use of Diasome’s proprietary Hepatocyte ... insulin to more effectively reach the liver’s metabolic cells, ...
(Date:3/30/2015)... Francisco, CA (PRWEB) March 30, 2015 ... tax incentives provided you the government, major companies are ... and local governments setting future mandates for renewable energy ... as an option. , Solara Power is a new ... several incentive programs available that allow qualifying homeowners to ...
Breaking Biology Technology:PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 2PlasmaTech Biopharmaceuticals' Partner Hanmi Pharmaceuticals Receives Marketing Approval For MuGard In Korea 3Sight Restoration Through Stem Cell Therapy - Subject of June Symposium of Experts 2Diasome Pharmaceuticals, Inc. Announces Notice of Allowance from US PTO for Liver Targeting System for Insulin 2Solara Power Announces Residential Solar Power with No Up-Front Fees 2
... VILLAGE, Nev., June 8 PDL BioPharma, Inc. (PDL) (Nasdaq: ... second quarter ended June 30, 2009 of approximately $125 million, ... 2008. The increase is due primarily to royalty revenues driven ... marketed by Genentech, and sales of Tysabri(R), which is marketed ...
... reductions in fasting plasma glucose, HbA1c and body weight ... 8 Intarcia Therapeutics, Inc. today presented results from ... delivery of exenatide) for the treatment of type 2 ... the American Diabetes Association in New Orleans, LA (June ...
... N.J., June 8 Celator Pharmaceuticals today announced ... extended therapeutic bioavailability and tumor cell selectivity of ... at the 14th Congress of the European Hematology ... (Abstracts 1398 and 383). , , "These ...
Cached Biology Technology:PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million 2PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million 3Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 2Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 3Intarcia Therapeutics, Inc. Presents ITCA 650 Phase 1b Study Results as a Late-Breaker at the American Diabetes Association 69th Scientific Sessions 4Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 2Celator(R) Pharmaceuticals Presents Data on the Activity of CPX-351 Against Leukemia at the European Hematology Association Congress 3
(Date:3/20/2015)... 19, 2015 Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ... - Global Strategic Business Report" report to their offering. ... Geometry in US$ Thousands. The report provides separate comprehensive analytics ... Japan , Europe , ... Rest of World. Annual estimates and forecasts are ...
(Date:3/17/2015)... 2015 MedNet Solutions , a ... study management systems, is pleased to announce that ... Outsourcing in Clinical Trials Southeast conference – March ... excellent forum for MedNet to showcase iMedNet ... (SaaS) eClinical technology platform. We strongly ...
(Date:3/12/2015)... March 12, 2015 The mascots of the ... Hospital, part of Wake Forest Baptist Medical Center. They ... the 2015 ACC Men,s Basketball Tournament. Young patients enjoyed ... and getting their autographs. Brenner Children,s Hospital ... is the only children,s hospital in northwest ...
Breaking Biology News(10 mins):Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... 2010 UT Southwestern Medical Center researchers have found new ... susceptible to stress than others. In a study of ... event, animals that were more susceptible to stress exhibited enhanced ... brain. Specifically, the cells that these animals produced after a ...
... Hemophilia, a disease linked with legends of European monarchs, frail ... people today. And the very treatments that can help ... treatment is infusion with an expensively produced protein that helps ... system fights the therapy, and in a subset of those, ...
... N.J. ―The Center for Secure and Resilient Maritime Commerce (CSR) ... report. Stevens was named by the US Department ... Centers of Excellence and was selected to lead a national ... 11 universities to partner with the DHS and serve as ...
Cached Biology News:New brain nerve cells key to stress resilience, UT Southwestern researchers find 2New brain nerve cells key to stress resilience, UT Southwestern researchers find 3Researchers harness the power of plants to fight hemophilia 2Researchers harness the power of plants to fight hemophilia 3Researchers harness the power of plants to fight hemophilia 4
5 minutes from gel band to purified DNA...
Enables rapid purification of double-stranded DNA fragments = 200 bp, including, for example, PCR reaction products, DNA fragments obtained in restriction enzyme digests, or double-stranded cDNA...
DTT, 25g...
AgarPlaque Plus Agarose 50 grams...
Biology Products: